Lipids & metabolic liver disease
Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD
Authors' conclusion
NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L are still at high risk of poor clinical outcomes. These findings support including 1-h PG ≥ 8.6 mmol/L as a component of the metabolic dysfunction definition.
Study context
- Population
- Consecutive participants with imaging assessments of fatty liver and a 75-g OGTT, enrolled June 2009 to May 2024
- Participants
- 1,154 / 161 / 1,026
- Exposure
- MASLD and NAFLD-non-MASLD vs non-fatty liver; 1-h PG ≥ 8.6 mmol/L vs <8.6 mmol/L
- MASLDn = 1,154
- NAFLD-non-MASLDn = 161
- Non-fatty livern = 1,026reference
- Outcome
- 1-h PG levels
Methodological detailsconsecutive participants
- Consecutive participants
Main finding
As reported in the abstract
- MASLD or NAFLD-non-MASLD vs Non-fatty liver: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Prevalence of advanced fibrosisNAFLD-non-MASLD with 1-h PG ≥ 8.6 mmol/L vs MASLD with or without 1-h PG ≥ 8.6 mmol/L · higher with NAFLD-non-MASLD with 1-h PG ≥ 8.6 mmol/L | P < 0.05 |
Association of 1-h PG ≥ 8.6 mmol/L with outcomes in MASLD or NAFLD-non-MASLD
- Moderate-to-severe steatosis
- P < 0.001
- ALT elevation
- P < 0.001
- Advanced fibrosis
- P = 0.03
- CVD
- P < 0.001
Original publication
Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD. Diabetes Res Clin Pract. Published 22 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →